PT Darya-Varia Laboratoria Tbk (ISX:DVLA) EBIT: Rp188,799 Mil (TTM As of Mar. 2026)

What is PT Darya-Varia Laboratoria Tbk EBIT?

PT Darya-Varia Laboratoria Tbk ISX:DVLA 73 EBIT is Rp188,799 Mil as of Mar. 2026. GuruFocus rates ISX:DVLA with a GF Score™ of 73/100 and a GF Value™ of Rp1,840.45 (Modestly Undervalued). The stock has 4 warning signs investors should review.

PT Darya-Varia Laboratoria Tbk's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was Rp72,978 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was Rp188,799 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PT Darya-Varia Laboratoria Tbk's annualized ROC % for the quarter that ended in Mar. 2026 was 11.35%. PT Darya-Varia Laboratoria Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 27.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PT Darya-Varia Laboratoria Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 13.07%.

PT Darya-Varia Laboratoria Tbk (ISX:DVLA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PT Darya-Varia Laboratoria Tbk's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	275528.62 * ( 1 - 24.21% )	/	( (1859492.182	+	1821560.657)	/ 2 )
=	208823.141098	/	1840526.4195
=	11.35 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2350265.761	-	149214.333	-	( 341559.246	-	max(0, 679928.674	-	1664526.199	+	341559.246	))
=	1859492.182

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2516208.197	-	227582.795	-	( 467064.745	-	max(0, 780931.446	-	1831261.822	+	467064.745	))
=	1821560.657

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

PT Darya-Varia Laboratoria Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	291912.028	/	( ( (494317.914 + max(587781.481, 0))	+	(496081.944 + max(561400.899, 0)) )	/	2 )
=	291912.028	/	( ( 1082099.395	+	1057482.843 )	/	2 )
=	291912.028	/	1069791.119
=	27.29 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(780506.976	+	448007.371	+	39019.089)	-	(149214.333	+	0	+	530537.622)
=	587781.481

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(818420.679	+	443399.043	+	80349.273)	-	(227582.795	+	0	+	553185.301)
=	561400.899

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PT Darya-Varia Laboratoria Tbk's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	188799.134	/	1445049.311
	=	13.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Darya-Varia Laboratoria Tbk EBIT Related Terms

PT Darya-Varia Laboratoria Tbk EBIT Historical Data

* Premium members only.

The historical data trend for PT Darya-Varia Laboratoria Tbk's EBIT can be seen below:

PT Darya-Varia Laboratoria Tbk EBIT Chart

PT Darya-Varia Laboratoria Tbk Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

211,634.68

201,244.37

191,706.54

209,809.18

220,220.63

PT Darya-Varia Laboratoria Tbk Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															104,399.50	59,245.72	55,368.86	1,206.55	72,978.01

ISX:DVLA vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PT Darya-Varia Laboratoria Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PT Darya-Varia Laboratoria Tbk EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Darya-Varia Laboratoria Tbk's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PT Darya-Varia Laboratoria Tbk's EV-to-EBIT falls into.

Save Embed

73GF Score

PT Darya-Varia Laboratoria Tbk ISX:DVLA

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PT Darya-Varia Laboratoria Tbk EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp188,799 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of Rp188,799 Mil mean?

PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a EBIT of Rp188,799 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Darya-Varia Laboratoria Tbk.

Is PT Darya-Varia Laboratoria Tbk's EBIT too high?

PT Darya-Varia Laboratoria Tbk's current EBIT is Rp188,799 Mil. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does PT Darya-Varia Laboratoria Tbk's EBIT compare to ZTS and UTHR?

PT Darya-Varia Laboratoria Tbk's EBIT of Rp188,799 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Darya-Varia Laboratoria Tbk. PT Darya-Varia Laboratoria Tbk's current EBIT is Rp188,799 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?

Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,840.45, compared to a current price of Rp1,595.00 — trading 13.3% below its estimated fair value. The current EBIT is Rp188,799 Mil. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current EBIT is Rp188,799 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued. The current stock price of Rp1,595.00 is trading 13.3% below its estimated GF Value™ of Rp1,840.45. GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.

Key valuation signals for ISX:DVLA:

EBIT: Rp188,799 Mil
GF Value™: Rp1,840.45 vs. price of Rp1,595.00 (13.3% below fair value)
GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Darya-Varia Laboratoria Tbk Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ISX:MERK ISX:PYFA ISX:PEHA XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692 UTHR VTRS NSE:DIVISLAB OSTO:SOBI TSE:4507 NBIX NSE:TORNTPHARM

Address Jalan. R.A. Kartini Kav. 8, 18th-19th Floor, South Quarter, Tower C, Jakarta, IDN, 12430

Website https://www.darya-varia.com

PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.

73GF Score

Get the complete analysis for ISX:DVLA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp1,595.00

Price

Rp1,840.45

GF Value

View ISX:DVLA Analysis

See EBIT data for all stocks →